Business, Health Care

Bristol Myers Squibb provides update on Phase 3 IDHENTIFY trial in patients with relapsed or refractory acute myeloid leukemia

PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #AML—Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or

Business, Media & Communications

Many U.S. cities including New York, San Francisco, LA and major metros throughout Florida utilize Everbridge to mitigate the compounding threat from overlapping crises: COVID-19 pandemic, wildfires and hurricanes

Serving Eight of the Ten Largest U.S. Cities, and Over 3,700 Municipalities and Counties Across the Country, Everbridge Enables Local Governments to Execute Best Practices to Keep Citizens Safe and Informed Amid Critical Events BURLINGTON, Mass.–(BUSINESS WIRE)–Everbridge, Inc. (NASDAQ: EVBG), the global

Health Care

Merck’s KEYTRUDA® (pembrolizumab) receives two new approvals in Japan

KEYTRUDA Now Approved for Patients With PD-L1-Positive Esophageal Squamous Cell Carcinoma Who Have Progressed After Chemotherapy and for a Six-Week Dosing Schedule Across All Adult Indications Six-Week Dosing Schedule for KEYTRUDA Now Approved in Japan, US and Europe KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck